Dylewski J S, Zackon H M, Latour A H, Berry G R
Rev Infect Dis. 1987 May-Jun;9(3):578-80. doi: 10.1093/clinids/9.3.578.
Mycobacterium szulgai is an unusual pathogen that accounts for less than 1% of all cases of non-tuberculosis mycobacterial infection. Infections with this organism usually involve the lung but may involve soft tissues. Although similar to tuberculosis in its clinical presentation, infection due to M. szulgai requires different management, and it is therefore important to distinguish disease caused by M. szulgai from that caused by M. tuberculosis. Isolation of M. szulgai implies the presence of clinical disease, and when the organism is identified, treatment based on sensitivity testing should be initiated. Although no standard recommendations for treatment exist, most infections due to M. szulgai have been treated with combined high doses of isoniazid, ethambutol, and rifampin for 18-24 months. M. szulgai has been isolated worldwide; the first case of infection reported from Canada is described, and the clinical presentation, microbiologic diagnosis, and therapeutic management of M. szulgai infections are reviewed.
苏尔加分枝杆菌是一种不常见的病原体,在所有非结核分枝杆菌感染病例中占比不到1%。这种病菌感染通常累及肺部,但也可能累及软组织。尽管其临床表现与结核病相似,但苏尔加分枝杆菌感染需要不同的治疗方法,因此区分苏尔加分枝杆菌引起的疾病与结核分枝杆菌引起的疾病很重要。分离出苏尔加分枝杆菌意味着存在临床疾病,一旦识别出该病菌,应根据药敏试验开始治疗。虽然目前尚无标准的治疗建议,但大多数苏尔加分枝杆菌感染采用高剂量异烟肼、乙胺丁醇和利福平联合治疗18至24个月。苏尔加分枝杆菌在世界各地均有分离报道;本文描述了加拿大报告的首例感染病例,并对苏尔加分枝杆菌感染的临床表现、微生物学诊断和治疗管理进行了综述。